Table 3 summarizes some of the most recent clinical trials for drugs targeting this pathway (specifically in HER2-positive breast cancer, or TNBC). Among the combinatorial approaches in trials, exploring the combination of an AKT inhibitor (Uprosertib) and an MEK1/2 inhibitor (trametinib) seems to be an innovative cross-pathway approach [118]. Here, AKT1 is linked to breast carcinoma.